ASH 2020: Focus on Myelodysplastic Syndromes
Hypomethylating agents (HMAs) are the current standard of care in patients with high-risk myelodysplastic ...
Many patients with myelodysplastic syndromes (MDS) are dependent on blood transfusions. Therefore, sufficient blood ...
Patients with cancer often face financial toxicity due to the effects of disease on the ability to work, as well as the ...
The Revised International Prognostic Scoring System (IPSS-R) is a useful tool to predict clinical outcomes in patients ...
The Revised International Prognostic Scoring System (IPSS-R) is the standard tool to predict prognosis for patients with ...
Research presented at the 62nd ASH Annual Meeting & Exposition indicates that the presence of cardiovascular disease ...
Histological and cytomorphological examinations are vital to diagnosis of myelodysplastic syndromes (MDS). But accurate ...
According to research presented at the 62nd ASH Annual Meeting & Exposition, combining pathology reviews with ...
A longitudinal research study out of an Austrian institute identified several disease-specific and patient-related ...
Studies have found that combining patient-reported outcomes (PROs) with more traditional disease classification systems, ...
Iron overload is linked to higher rates of complications and mortality in patients with myelodysplastic syndromes (MDS). ...
Iron overload has been identified as a common and important issue in the management of patients with myelodysplastic ...
A mounting body of evidence shows that gender plays an essential role in many facets of myriad diseases, such as risk ...
A study presented at the 62nd ASH Annual Meeting & Exposition demonstrated that allogeneic hematopoietic cell ...
A study presented at the 62nd ASH Annual Meeting & Exposition found that patients with myelodysplastic syndromes ...
Scientists are just beginning to explore the effects of COVID-19 (SARS-CoV-2) on specific populations of patients with ...
Advertisement
Advertisement
